Bitcoin and Ethereum price update

Bitcoin started the day trading at US$98,509, reflecting a 0.96 percent decline from its previous close. The day’s trading range saw a high of US$100,797 and a low of US$96,026.

Ether is priced at US$2,803.29, marking a 0.87 percent increase over 24 hours. The cryptocurrency reached an intraday high of US$2,870.86 and a low of US$2,634.37 on Tuesday (February 4).

Altcoin price update

SOL is currently valued at US$206.53, 1.6 percent lower across 24 hours, after hitting a daily high of US$218.29 and a low of US$202.45.

XRP fell to US$2.44 before North American markets opened and rose to its highest value of US$2.70 at 8:00 a.m. UTC. The cryptocurrency is currently valued at US$2.56.

SUI is trading at US$3.63, a 5.2 percent boost, after a daily high of US$3.89 and a low of US$3.44.

Meanwhile, ADA is still up, priced at US$0.7698, reflecting a 2.1 percent increase over 24 hours. Its highest price on Wednesday was US$0.7861 and its lowest was US$0.7242.

Crypto news to know

Trump’s tariff threats over the weekend led to a sharp selloff in the cryptocurrency market, with Bitcoin dropping from around US$105,000 to a low of US$92,000 before rebounding above US$100,000 on Monday.

The announcement of a temporary pause on tariffs against Mexican and Canadian goods helped stabilize market sentiment.

While Bitcoin managed to recover some losses, other cryptocurrencies faced continued pressure. Ethereum, Dogecoin, and several altcoins posted double-digit declines.

Even Trump’s own meme coin saw one of the steepest drops, trading at around US$19 on Monday—down 75 percent from its all-time high set during his second inauguration.

Meanwhile, in Washington, Trump’s administration is assessing the feasibility of establishing a U.S. Bitcoin reserve.

White House crypto czar David Sacks stated that an internal working group is reviewing the concept, though no formal decisions have been made. Sacks emphasized that the administration is in the early stages of developing its digital asset policies.

Investor Insight

Anteros Metals’ forward-thinking, diversified exploration strategy that leverages innovative data science to target high-potential mineral deposits offers a compelling opportunity for savvy investors to gain exposure and generate value in multiple stages of mineral exploration.

Overview

Anteros Metals (CSE:ANT) is a dynamic multimineral exploration company leveraging modern data science methodologies to systematically advance its projects across Newfoundland and Labrador, Canada. Focused on sustainable and cost-effective exploration, Anteros targets high-value deposits in underexplored yet geologically rich regions. With a portfolio covering 2,775 hectares and commodities critical to global technology and energy transitions, Anteros positions itself as a leading innovator in the junior mining sector.

The company’s strategic approach prioritizes asset acquisition in underexplored yet resource-rich regions, positioning Anteros to capitalize on growing global demand for critical and base metals. Its properties encompass nine metals and minerals, five of which are classified as critical minerals, reflecting the company’s alignment with the accelerating energy transition and technological advancement.

Applying proprietary algorithms and integrating historical exploration data allow the company to significantly reduce exploration risk while accelerating project timelines. This streamlined, data-driven approach underpins Anteros’ ability to generate long-term shareholder value through exploration, joint ventures and operational partnerships.

Furthermore, Anteros follows a structured approach to exploration, with projects strategically positioned across different stages of the mineral exploration lifecycle. By maintaining a balanced portfolio across various exploration stages, Anteros ensures a steady progression of projects toward resource definition and development.

Company Highlights

• Four 100 percent owned properties in Newfoundland and Labrador targeting critical and base metals. Commodities include copper, cobalt, nickel, manganese, zinc and others vital for green technologies.
• The flagship Knob Lake iron-manganese project is an advanced exploration project with a historical resource located near significant iron ore infrastructure in Schefferville, Quebec.
• Haven Steady is a proven VMS asset accessible by road and hosts silver-lead-zinc mineralization with high-grade intersections and untapped geophysical anomalies.
• The Strickland project includes seven mineralized zones with significant silver-lead-zinc and gold potential, located near the prolific Hope Brook gold deposit.
• The Hopedale asset has a nickel-copper-cobalt focus, situated 90 kilometers south of Vale’s Voisey’s Bay in a geologically favorable zone with unexplained geochemical anomalies and untested electromagnetic conductors.
• Anteros follows a structured approach, with projects at various exploration stages: prospecting (Hopedale), early-stage (Haven Steady), intermediate (Strickland), and advanced exploration (Knob Lake). By balancing its portfolio, Anteros ensures a continuous pipeline of project advancement, reducing risks and maintaining steady value creation.
• The company is led by an experienced team with over a century of combined expertise in exploration, mining and financial markets, ensuring robust project execution.

Key Projects

Knob Lake

Located within the Western Labrador Trough, just 2.5 km south of Schefferville, Québec, Knob Lake benefits from its proximity to extensive infrastructure, including rail lines, roads and nearby iron ore processing facilities. The property, covering 0.75 square kilometers across three claims, targets a superior-type iron deposit hosted within the Sokoman Formation, renowned for its high-grade direct shipping ore (DSO) potential. This property is in proximity to significant iron ore operations, including Tata Steel’s Timmins Mine and the historical James, Ruth Lake and Redmond mines.

Historical exploration includes 2,746 meters of diamond drilling, which delineated a historical resource of 5.08 million tons (Mt) at 54.7 percent iron (measured and indicated) and 643,800 tons at 51.5 percent iron (inferred)¹. The deposit remains open along strike and at depth, indicating significant potential for resource expansion.

As Anteros’ flagship project, Knob Lake, is in the advanced exploration stage, with historical drilling confirming significant resources of iron and manganese. The project benefits from detailed modeling, infrastructure readiness, and proximity to established mining operations.

Future exploration plans involve leveraging recent digital modeling and geophysical surveys to refine the geological understanding and define additional high-grade zones. Knob Lake’s excellent access to global shipping routes enhances its economic viability, positioning it as a flagship project for Anteros Metals.

^{¹This historical mineral resource estimate is from a Technical Report entitled Technical Report: Schefferville Area Phase I DSO Iron Projects Resource Update, Western Labrador – NE Québec, Canada by Maxime Dupéré dated June 27, 2014 and is filed on SEDAR (www.sedar.com). The Technical Report was prepared in accordance with National Instrument 43-101 – Standards of Disclosure for Mineral Projects (NI 43-101), NI 43-101F1, and with CIM standards and Mineral Resource best practices. The independent QP believed project data was suitable for mineral resource estimation at that time. The stated resource uses an iron cut-off grade of 50%, and grades were not capped. An independent Qualified Person will be required to compile and validate historic Property data, model the data, and estimate the mineral resource to obtain a current mineral resource. It is envisaged that this will involve open pit optimization. A qualified person has not done sufficient work to classify the historical estimate as a current mineral resource. Anteros Metals Incorporated is not treating the historical estimate as a current mineral resource.}

Haven Steady

Haven Steady is located 40 km southeast of Buchans in the Central Newfoundland Gold Belt, a prolific region for volcanogenic massive sulphide (VMS) deposits. Haven Steady is situated in a district renowned for Kuroko-style polymetallic mineralization.

The property hosts significant silver-lead-zinc mineralization along a 1,000-meter strike length, identified through 8,048 meters of historical drilling. Key intersections include up to 4.16 percent copper over 1.3 meters and multiple gold-enriched zones exceeding 1 gram per ton (g/t) gold. The deposit lies within altered felsic volcanics, typical of Kuroko-style VMS systems, and is surrounded by untested geophysical anomalies. This geological setting is comparable to the nearby Duck Pond mine, which produced high-grade copper and zinc. Future plans focus on detailed geophysical studies and phased drilling campaigns to test high-priority targets and expand known mineralized zones. The presence of enriched gold and copper zones within a proven VMS district makes Haven Steady a key asset for Anteros Metals.

Strickland

Strickland lies in the Central Newfoundland Gold Belt, a region with prolific epithermal gold and VMS deposits. The property features seven mineralized zones with a combined strike length exceeding 2 km. The mineralization is hosted within submarine felsic volcanic units, providing predictable horizons for efficient exploration.

Historical drilling of 7,857 meters has delineated zones with significant grades, including a historical mineral inventory of 260,000 tons at 195 g/t silver and 5.25 percent lead-zinc in the Main Zone². Historical assays from quartz veins report gold grades up to 17.9 g/t gold, emphasizing the property’s epithermal gold potential.

Proximity to the Hope Brook gold deposit, which holds an indicated resource of 5.5 Mt at 4.77 g/t gold³, further underscores the potential of Strickland. Upcoming exploration activities include advanced geophysical surveys, trenching and targeted drilling to define and expand the resource base.

^{²The resource inventories described are considered ‘historical’ in nature as defined by National Instrument 43-101, and do not conform to CIM Resource Classification Definitions.The historical estimate was reported by D.R. Prince in a 1981 Falconbridge Nickel Mines Ltd. report entitled “Summary of Work Performed from 1977 to 1980 on the Strickland-Porter Fee Simple Property, Newfoundland”. A qualified person has not done sufficient work to classify the historical estimates of the Strickland Deposit as current mineral resources. As a result, Anteros Metals Incorporated is not treating these historical estimates as current mineral resource estimates, but believes that these historic results provide an indication of the potential of the property and are relevant from a continuing exploration perspective.}

^{³Cullen, M.,Harrington, M. and Burke, J. (2021): NI 43-101 Technical Report for the Hope Brook Gold Project, Newfoundland and Labrador Canada. Prepared for Big Ridge Gold Corp. Effective date April 6th, 2021.}

Hopedale

Located in Labrador, 80 km south of the world-class Voisey’s Bay Mine, the Hopedale property targets magmatic nickel-copper-cobalt mineralization within the Churchill-Nain Suture Zone. The project spans 20 square kilometers and features troctolitic rocks intruded by northeast-trending gabbro dykes, a geological setting favorable for disseminated nickel-copper-cobalt mineralization.

Hopedale’s historical stream sediment sampling programs identified unexplained geochemical anomalies, with elevated nickel, copper and cobalt values near untested electromagnetic conductors. This project represents a significant greenfield exploration opportunity. Future exploration will focus on high-resolution geophysical surveys and drilling programs to evaluate these anomalies. Hopedale’s proximity to Voisey’s Bay and its favorable geological setting position it as a high-potential greenfield project for critical minerals essential to the clean energy transition.

Leadership Team

Trumbull Fisher – CEO

A seasoned professional with 17 years of experience in mining and capital markets, Trumbull Fisher has successfully led multiple resource companies and brings a wealth of expertise in project generation and financing. Fisher has grown both private and public resource companies in roles as chairman, president, board member and advisor. Fisher holds a BA from Carlton University.

Alan Rootenberg – CFO

With over 35 years in corporate finance, Alan Rootenberg’s extensive knowledge ensures Anteros maintains its strong financial foundation. Rootenberg holds a CPA, CA designation and has extensive experience in mineral and oil and gas exploration, serving as chief executive officer, chief financial officer and director to publicly listed companies.

Bill Kennedy – Director

Bill Kennedy is a second-generation prospector with 12 years of experience in exploration-centric business operations and development in Newfoundland and Labrador, and has over 20 years of experience in information technologies. Blending his passion for tech and mining, Kennedy continues to pioneer data science systems for mineral target vectorization.

Wesley Keats – Director

With an extensive background in mining and exploration, including global experience in seven countries, Wes Keats has 22 years of experience in the metals industry, having worked privately for major and junior mining companies. He is a fourth-generation prospector in Newfoundland and a current partner of Newfoundland based exploration services and mining development company Planet X. Keats was the co-recipient of the PDAC Bill Dennis award for significant contributions made towards a Canadian discovery.

Chris Morrison – Director

Chris Morrison has experience in the operation of multiple corporations, mining sector marketing and communications, and capital markets. Morrison is the marketing manager for Planet X Exploration and multiple public client companies, and the principal of SJ AV Studio – a digital multimedia audio/visual production facility focused on mining sector press and marketing material curation and distribution.

Bitcoin and Ethereum price update

Bitcoin started the day trading at US$98,509, reflecting a 0.96 percent decline from its previous close. The day’s trading range saw a high of US$100,797 and a low of US$96,026.

Ether is priced at US$2,803.29, marking a 0.87 percent increase over 24 hours. The cryptocurrency reached an intraday high of US$2,870.86 and a low of US$2,634.37 on Tuesday (February 4).

Altcoin price update

SOL is currently valued at US$206.53, 1.6 percent lower across 24 hours, after hitting a daily high of US$218.29 and a low of US$202.45.

XRP fell to US$2.44 before North American markets opened and rose to its highest value of US$2.70 at 8:00 a.m. UTC. The cryptocurrency is currently valued at US$2.56.

SUI is trading at US$3.63, a 5.2 percent boost, after a daily high of US$3.89 and a low of US$3.44.

Meanwhile, ADA is still up, priced at US$0.7698, reflecting a 2.1 percent increase over 24 hours. Its highest price on Wednesday was US$0.7861 and its lowest was US$0.7242.

Crypto news to know

Trump’s tariff threats over the weekend led to a sharp selloff in the cryptocurrency market, with Bitcoin dropping from around US$105,000 to a low of US$92,000 before rebounding above US$100,000 on Monday.

The announcement of a temporary pause on tariffs against Mexican and Canadian goods helped stabilize market sentiment.

While Bitcoin managed to recover some losses, other cryptocurrencies faced continued pressure. Ethereum, Dogecoin, and several altcoins posted double-digit declines.

Even Trump’ own meme coin saw one of the steepest drops, trading at around US$19 on Monday—down 75 percent from its all-time high set during his second inauguration.

Meanwhile, in Washington, Trump’s administration is assessing the feasibility of establishing a U.S. Bitcoin reserve.

White House crypto czar David Sacks stated that an internal working group is reviewing the concept, though no formal decisions have been made. Sacks emphasized that the administration is in the early stages of developing its digital asset policies.

Nuvau Minerals (TSXV:NMC) revitalizes critical mineral production in Quebec with its flagship project, the Matagami Mining Camp, which represents a premier opportunity in the Abitibi Greenstone Belt.

Quebec’s Abitibi Greenstone Belt is renowned for its high-grade deposits and significant production history and is recognized as a Tier 1 jurisdiction with exceptional mining infrastructure and skilled labor. Nuvau Minerals has an agreement to acquire the Matagami Mining Camp from Glencore. The camp has a rich mining history with 60 years of production and nearly 60 million tons mined across 12 past mines.

The Matagami Mining Camp covers over 1,300 square kilometers, comprising more than 2,500 claims. The property offers exceptional exploration potential for critical minerals, particularly zinc and copper. The Matagami Mining Camp has produced nearly 60 million tons of ore over 60 years of continuous operation.

The property features a 3,000-ton-per-day concentrator, last operated by Glencore in 2022. This infrastructure not only reduces the capital requirements for reactivation but also accelerates the timeline for potential production. Extensive geological and operational data inherited from Glencore provides a strong foundation for efficient exploration and development.

Company Highlights

• Nuvau Minerals has an agreement to acquire the Matagami Mining Camp from Glencore, a historic mining camp with 60 years of production history and nearly 60 million tons mined across 12 past mines.
• The flagship Matagami Mining Camp spans more than 1,300 square kilometers with more than 2,500 claims in Quebec’s Abitibi Greenstone Belt. The project includes a 3,000-ton-per-day concentrator operated by Glencore until June 2022.
• Nuvau has invested nearly $30 million since early 2022 in a three-year exploration program to discover critical minerals, primarily zinc and copper, leveraging highly prospective targets across the property.
• The companyaims to re-establish the Matagami Mining Camp as a leading critical minerals producer by leveraging historical data, robust infrastructure, and modern exploration techniques.
• Quebec’s Abitibi Greenstone Belt is globally recognized as a Tier 1 jurisdiction with exceptional mining infrastructure and skilled labor.
• Approximately $25 million has already been invested in the property, with the earn-in phase with Glencore expected to be completed by 2025.

This Nuvau Minerals profile is part of a paid investor education campaign.*

Click here to connect with Nuvau Minerals (TSXV:NMC) to receive an Investor Presentation

Amgen reports strong Q4, will focus on trials in 2025

Amgen’s financial results for Q4 and the full 2024 year reveal quarterly revenue of over US$9 billion, beating analysts’ estimates of US$8.87 billion. Revenue for the year came in at US$33.42 billion, ahead of projections of US$33.19 billion, driven by an overall increase in the volume of demand for its products.

An 11 percent year-on-year increase in product sales was primarily by the pharmaceutical company’s strong performance in oncology and immunology therapies, along with sales of Repatha, which treats high cholesterol, and Evenity, which treats osteoporosis in postmenopausal women.

Earning per share (EPS) also beat estimates of US$5.08, coming in at US$5.31.

Amgen performance, February 4, 2025.

Chart via Google Finance.

Looking ahead, Amgen’s revenue guidance for fiscal year 2025 was between US$34.3 billion and US$35.7 billion, in line with the average estimate of US$34.53 billion. Phase III trials of its weight management candidate MariTide, a dual GIP and GLP-1 receptor modulator, are expected to begin in H1 2025.

While Amgen’s shares have decreased by over ten percent year-on-year, they have increased by nearly 11 percent year-to-date. The stock closed with a marginal gain of 0.05 percent at US$289.01.

Merck beats on revenue, but Gardasil sales decline

Merck fell by nearly 11 percent ahead of the opening bell on Tuesday after its Q4 and full-year 2024 financial results showed adjusted sales revenue for its key vaccine, despite exceeding sales and profit expectations.

The company reported revenue of US$15.62 billion, beating analysts estimates of US$15.55 billion.

Earnings per share for the quarter were also ahead of expectations, US$1.72 compared to US$1.69; however, earnings per share were US$6.74 for the full year, compared to analysts’ estimates of US$7.62.

Sales reached US$15.6 billion in Q4, an increase of 7 percent from the prior year.

Full-year sales also rose by 7 percent to US$64.2 billion, driven by sales of Keytruda, the company’s leading cancer therapy. Keytruda brought in US$29.5 billion, representing an annual growth of 18 percent.

The company also announced positive topline results from a Phase 3 trial evaluating a subcutaneous formulation of pembrolizumab used in combination with Keytruda in adult patients with metastatic non-small cell lung cancer.

However, sales of Gardasil and Gardasil 9, two HPV vaccines, declined by 3 percent to US$8.6 billion.

Merck performance, February 4, 2025.

Chart via Google Finance.

For its 2025 fiscal year, Merck expects full-year adjusted EPS to be between US$8.88 and US$9.03, and revenue to fall somewhere between US$64.1 billion and US$65.6 billion. Analysts had been projecting EPS of US$9.13 and revenue of US$67.07 billion. The company also withdrew its US$11 billion sales target for Gardasil by 2030.

“This sales range reflects a decision to temporarily pause shipments of GARDASIL/GARDASIL 9 into China beginning February 2025 through at least mid-year,” the company said in an accompanying statement. According to Biopharma Dive, CEO Rob Davis clarified in the firm’s earnings call that the pause will “facilitate a more rapid reduction of inventory and help support the financial position” of its Chinese distribution partner, Zhifei Biological Products.

“China still represents a significant long-term opportunity for Gardasil given the large number of females, and now males with our recent approval, that are not yet immunized,” Davis said.

Pfizer discusses Seagen acquisition impact and 2025 outlook

Pfizer’s Q4 and 2024 financial results show revenue at US$17.8 billion, an increase of 22 percent compared to the previous year and exceeding expectations of US$14.31 billion. Revenue, excluding COVID-19-related therapies, was largely driven by Seagan’s portfolio of cancer therapies following its acquisition in December 2023.

However, full-year revenue fell slightly short at US$63 billion, compared to projections of US$63.6 billion. EPS was also below analysts’ estimates of US$0.71, coming in at US$0.63.

Its share price fell by 4.3 percent in early trading and ended the day down 1.26 percent.

Pfizer performance, February 4, 2025.

Chart via Google Finance.

Looking ahead, Pfizer will continue to focus on growing its pipeline of cancer drugs in 2025, with three potential therapies awaiting regulatory approval in 2025. The company will also initiate clinical trials for therapies related to inflammation, immunology, and internal medicine. For its 2025 fiscal year, Pfizer is projecting revenue of between US$61 billion and US$64 billion, aligning with the average estimate of US$63.22 billion.

Amgen reports strong Q4, will focus on trials in 2025

Amgen’s financial results for Q4 and the full 2024 year reveal quarterly revenue of over US$9 billion, beating analysts’ estimates of US$8.87 billion. Revenue for the year came in at US$33.42 billion, ahead of projections of US$33.19 billion, driven by an overall increase in the volume of demand for its products.

An 11 percent year-on-year increase in product sales was primarily by the pharmaceutical company’s strong performance in oncology and immunology therapies, along with sales of Repatha, which treats high cholesterol, and Evenity, which treats osteoporosis in postmenopausal women.

Earning per share (EPS) also beat estimates of US$5.08, coming in at US$5.31.

Amgen performance, February 4, 2025.

Chart via Google Finance.

Looking ahead, Amgen’s revenue guidance for fiscal year 2025 was between US$34.3 billion and US$35.7 billion, in line with the average estimate of US$34.53 billion. Phase III trials of its weight management candidate MariTide, a dual GIP and GLP-1 receptor modulator, are expected to begin in H1 2025.

While Amgen’s shares have decreased by over ten percent year-on-year, they have increased by nearly 11 percent year-to-date. The stock closed with a marginal gain of 0.05 percent at US$289.01.

Merck beats on revenue, but Gardasil sales decline

Merck fell by nearly 11 percent ahead of the opening bell on Tuesday after its Q4 and full-year 2024 financial results showed adjusted sales revenue for its key vaccine, despite exceeding sales and profit expectations.

The company reported revenue of US$15.62 billion, beating analysts estimates of US$15.55 billion.

Earnings per share for the quarter were also ahead of expectations, US$1.72 compared to US$1.69; however, earnings per share were US$6.74 for the full year, compared to analysts’ estimates of US$7.62.

Sales reached US$15.6 billion in Q4, an increase of 7 percent from the prior year.

Full-year sales also rose by 7 percent to US$64.2 billion, driven by sales of Keytruda, the company’s leading cancer therapy. Keytruda brought in US$29.5 billion, representing an annual growth of 18 percent.

The company also announced positive topline results from a Phase 3 trial evaluating a subcutaneous formulation of pembrolizumab used in combination with Keytruda in adult patients with metastatic non-small cell lung cancer.

However, sales of Gardasil and Gardasil 9, two HPV vaccines, declined by 3 percent to US$8.6 billion.

Merck performance, February 4, 2025.

Chart via Google Finance.

For its 2025 fiscal year, Merck expects full-year adjusted EPS to be between US$8.88 and US$9.03, and revenue to fall somewhere between US$64.1 billion and US$65.6 billion. Analysts had been projecting EPS of US$9.13 and revenue of US$67.07 billion. The company also withdrew its US$11 billion sales target for Gardasil by 2030.

“This sales range reflects a decision to temporarily pause shipments of GARDASIL/GARDASIL 9 into China beginning February 2025 through at least mid-year,” the company said in an accompanying statement. According to Biopharma Dive, CEO Rob Davis clarified in the firm’s earnings call that the pause will “facilitate a more rapid reduction of inventory and help support the financial position” of its Chinese distribution partner, Zhifei Biological Products.

“China still represents a significant long-term opportunity for Gardasil given the large number of females, and now males with our recent approval, that are not yet immunized,” Davis said.

Pfizer discusses Seagen acquisition impact and 2025 outlook

Pfizer’s Q4 and 2024 financial results show revenue at US$17.8 billion, an increase of 22 percent compared to the previous year and exceeding expectations of US$14.31 billion. Revenue, excluding COVID-19-related therapies, was largely driven by Seagan’s portfolio of cancer therapies following its acquisition in December 2023.

However, full-year revenue fell slightly short at US$63 billion, compared to projections of US$63.6 billion. EPS was also below analysts’ estimates of US$0.71, coming in at US$0.63.

Its share price fell by 4.3 percent in early trading and ended the day down 1.26 percent.

Pfizer performance, February 4, 2025.

Chart via Google Finance.

Looking ahead, Pfizer will continue to focus on growing its pipeline of cancer drugs in 2025, with three potential therapies awaiting regulatory approval in 2025. The company will also initiate clinical trials for therapies related to inflammation, immunology, and internal medicine. For its 2025 fiscal year, Pfizer is projecting revenue of between US$61 billion and US$64 billion, aligning with the average estimate of US$63.22 billion.